{"name":"Forma Therapeutics, Inc.","slug":"forma-therapeutics-inc","ticker":"","exchange":"","domain":"forma.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Etavopivat Tablets High dose","genericName":"Etavopivat Tablets High dose","slug":"etavopivat-tablets-high-dose","indication":"Sickle cell disease","status":"phase_3"},{"name":"Etavopivat Tablets Low dose","genericName":"Etavopivat Tablets Low dose","slug":"etavopivat-tablets-low-dose","indication":"Sickle cell disease","status":"phase_3"},{"name":"Etavopivat tablets","genericName":"Etavopivat tablets","slug":"etavopivat-tablets","indication":"Sickle cell disease","status":"phase_3"}]}],"pipeline":[{"name":"Etavopivat Tablets High dose","genericName":"Etavopivat Tablets High dose","slug":"etavopivat-tablets-high-dose","phase":"phase_3","mechanism":"Etavopivat activates the Nrf2 (nuclear factor erythroid 2-related factor 2) pathway to increase antioxidant defenses and reduce hemolysis in red blood cells.","indications":["Sickle cell disease","Beta-thalassemia"],"catalyst":""},{"name":"Etavopivat Tablets Low dose","genericName":"Etavopivat Tablets Low dose","slug":"etavopivat-tablets-low-dose","phase":"phase_3","mechanism":"Etavopivat activates the KCNQ1 potassium channel to increase fetal hemoglobin (HbF) production in red blood cells.","indications":["Sickle cell disease"],"catalyst":""},{"name":"Etavopivat tablets","genericName":"Etavopivat tablets","slug":"etavopivat-tablets","phase":"phase_3","mechanism":"Etavopivat activates the protein kinase PKC (protein kinase C) to increase fetal hemoglobin (HbF) production, thereby reducing sickling and hemolysis in red blood cells.","indications":["Sickle cell disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNZTRmZmdiWFY1cWEzdzBoSmhhZWw1bnd0UmtJZGFFMlY2dTlELWxmbzVlN0Y2enZkNUZsa2psZzlhMzB5Z2Y0QVR4dk02b05rRmppSVVoRS01VmNJYWoxRVd0M2syMGZUQldhWjdDV0s0QW4tSUlmb0dCTG5NdU9NazdHbjlPdkVpU3dnazI5cUFjYVBMX0NGcmlfbDltVHlLcTV2b1JWWkVfQXpjdVoycg?oc=5","date":"2025-11-13","type":"pipeline","source":"Stock Titan","summary":"Salarius (NASDAQ: SLRX), Decoy merge; $14M cash backs IMP3ACT peptide therapeutics - Stock Titan","headline":"Salarius (NASDAQ: SLRX), Decoy merge; $14M cash backs IMP3ACT peptide therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNZ05nTEdJS2xvdkY1XzJwbTd1M0FEenk0SkZSZDJxSGJMa3Rmdl9EYWhJS0x3amVxOTdLcG9yRVNiWWIyMVlXNDMwS3JsMnduR3V3ejNVc0sxRElkZE9HOUx2aEY4RGRhekVqeElOZWtFSDBzcEhMcmNBNUNRYWo0c2NtckdMb203VXJxckZEdGVQZ0d3dFpCUVFuQVJBOXpmSGVBMExaM3k?oc=5","date":"2025-10-06","type":"pipeline","source":"Investing.com South Africa","summary":"KalVista Pharmaceuticals appoints new COO and CPO By Investing.com - Investing.com South Africa","headline":"KalVista Pharmaceuticals appoints new COO and CPO By Investing.com","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxOS3phTzdFQzJjUzJpYlkzY3NWeGoySzRaaGpCY2NJQW5vSEVjMTBqX2tUOUFJbDFpVV9OSWduaTB2NERNdlpjZ0QyQWg2WlQxb0xKZHVnUUxmOVd0TmlhSk9HRzVGS3F5T0NyTzhGVE5hTG5kR0Jfc0V3R1lfQVZoMnd4RkZjdWV1U1piOHNuUk9XTjI0MUVQWGVlcmNiQ0c2ajc5bWVBaXZBNk5QaGZ2SVk4aHN2ckFJYlpYLVJmdVVoYm1Ob1hJclNybTFpTEJsdTRXMHRNNVR0bmpaZ0dqYTdvS3p3elFBMnZpRU4wUmJEMmg4M3NwMXlaNndIYVRfbnpockFKOXJwNERLR28xRm1R?oc=5","date":"2025-09-22","type":"pipeline","source":"globenewswire.com","summary":"Thalassemia Treatment Market to Witness Significant Growth by 2034 Driven by Novel Drug Development | DelveInsight - globenewswire.com","headline":"Thalassemia Treatment Market to Witness Significant Growth by 2034 Driven by Novel Drug Development | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxNSHktT29jMU1aOS10TWVveVhDUmk0Zm1ZQWh4VUdtSFNwaHhSTk1TejJxaEtwOTFITm1XWnhaM2ZyTUdxTUhlN2dqYUVOQXpJaE5RYVFRUXVhZ19tYmhtMHp3M0Z4UGFQNkhwNTF6U1MwNFJJYUJsZjZrVlhCSVFGT0N1NTJJMWk2R3IzQVFON2hOcDZzclZwWm0yS1dVcVpTRjJLQk00VjJHUXg1NmhMYmo3MXRoaWJ2TVNjMEV5WTBEN3lQRzBNS08wRklpZW1GUXN1V2ZTeHd6ZGw2VTlpcWNlX3lIUnBzR24teDdlMlZ5ell3ZzJVZ0NQTWpkbjIzNzFJak1FZ2hXUzJhcnV3Tg?oc=5","date":"2023-07-11","type":"trial","source":"PR Newswire","summary":"Sickle Cell Disease Clinical Trial Pipeline Accelerates as 40+ Pharma Companies Rigorously Developing Drugs for the Market Entry - PR Newswire","headline":"Sickle Cell Disease Clinical Trial Pipeline Accelerates as 40+ Pharma Companies Rigorously Developing Drugs for the Mark","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxONzNKZUFWb0ZWRURkMXdqa1dzRHZ2dlZNSl9zX3dfZnFGb0xrdjN4ZmFtcXRPV1BZN0tleXBNMXQ5U1VMUTlyb1RrZWM3OWdOWE5aY1JpTFYtRHhkSXFDS2lwdVhsS3hnczIyYTM1SVQ1Tk03WGJFbktkY3RyeDJtNEhEV2Qwd0pHMkd5NWRiRGJZQQ?oc=5","date":"2022-10-17","type":"deal","source":"Pharmaceutical Technology","summary":"Novo Nordisk acquires Forma Therapeutics for $1.1bn - Pharmaceutical Technology","headline":"Novo Nordisk acquires Forma Therapeutics for $1.1bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPR3pnRjBSMlFvdXFaa1VQSFdjT2twdUNSOGZHNXhjZHl3aE5tTk9mWXpvamYyclFZZlVIWlZQWXEya3ZTaE5JbUNtLUVaN0RyUXowS19WLS1GWXc3ZHZwZ09SUWM1U05HRzBndTBFSGQ5TzEtcmFpRXlaYVFEUFVqT28zSHlYNVlZcjVwaFpXR2tFZw?oc=5","date":"2022-09-01","type":"pipeline","source":"Fierce Biotech","summary":"Novo Nordisk ponies up $1.1B for Forma in effort to shape up sickle cell disease market - Fierce Biotech","headline":"Novo Nordisk ponies up $1.1B for Forma in effort to shape up sickle cell disease market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOSFM2MzlzT0xab2RYUVBjT2FNbllvOXpqOWh1aF82RTc5V0p6ZW1PRmJIRHd5eFpOVmRPZHk1ZGhJVUtsclVDZmIxeEcyQTRPYzdxTWxoU2xNZGs0TkxURmlGbDhBVjJlNlZhVkhOSkVTejBFNGlBWlhyZzZyemNRWjZlSC1iV3J6X1NITWYtQkRHYkFaYm1pM09iZWFwZFZF?oc=5","date":"2022-09-01","type":"pipeline","source":"BioPharma Dive","summary":"With rare acquisition, Novo Nordisk makes $1B bet on sickle cell disease drug - BioPharma Dive","headline":"With rare acquisition, Novo Nordisk makes $1B bet on sickle cell disease drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPdFVwcFA0azhIVzdKUlRVWGZBOEpVNjl6N2JBM2VyLXVJNFdnYUtFb3hCNVVEWHQ2bWd3bUxVdkdrRUVpLUlCNVNyLXlmTTN6LU5VeVlCRnhJdzZCZ3ZwWF9VVUs2eUFQU3ZBSV96dWNEdmhnMUIzSEV3TWdGWGpnc0ZwZVVMSWFCSno0Y0plTC1INzJ5YmxEUmtXSW5SNGtBV2x3?oc=5","date":"2022-09-01","type":"deal","source":"reuters.com","summary":"Novo Nordisk to acquire Forma Therapeutics in $1.1. bln deal - reuters.com","headline":"Novo Nordisk to acquire Forma Therapeutics in $1.1. bln deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQN2RxdEp3RjBEWkd3ejRFZ0ZMeUl5cnlpUVFzTUhqakJoV0oweVlEb2dPLXYtUW52SEJyZkltTjA3YzJUWktXaWVncmI5Sml0eGVPSUJLT2x1R29zVHp0QnZ5dE02X01EWjZXc0JqXzktNlUyRHlqZnAwNEV2RDI1eVJtY01RNGs?oc=5","date":"2022-09-01","type":"deal","source":"Medical Marketing and Media","summary":"Novo to buy Forma Therapeutics for $1.1B - Medical Marketing and Media","headline":"Novo to buy Forma Therapeutics for $1.1B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxPd1ZFWEt5NHM3Z0tWcXkxbkxneFdEeHFWNlMtLUNfazVKR0RxS180Y2N6Vk1hR1NHdWZHWnVYVll3TkJVUTVQMk05VUpJUldWbDdSOGRnclhBbXRfY0dhM1dsUjdrdmtKZ25iX3g4VjVWalNYMnZfMElfS2c0bzhibG9tSVJoNmppMGs4MEp2eFR0bnZiMlRwbWNURkh3R2hSZzFVSC13SWFIdFBLTXF5aUxvYmRNekstLWszakprRExZYmxqZmN0SHVEUEpjWERwc1ZVNTZQNl9iVFkxbUhxT1ljSmxadU1UM19QYmFPbnhNQW10Y0twTW5RSQ?oc=5","date":"2022-09-01","type":"deal","source":"Business Wire","summary":"Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders - Business Wire","headline":"Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE1kOEQ4ajFzREg2cHB3WVBfSk5JblNia2lnVjhnWE0wcWp6ZFFWdXJQdjk2dTBaZnpDaDR3QnNWRGstOEYxWmU3SUhReS1aTkJNeVZmX0d2Ukx2VDBOOURMbnF5cGF0U1BpeDJIRE4zcjJjOTBX?oc=5","date":"2022-07-06","type":"pipeline","source":"Al Día News","summary":"Agustín Melián, new EVP, Head of Research and Development at Forma - Al Día News","headline":"Agustín Melián, new EVP, Head of Research and Development at Forma - Al Día News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQQ2NFUUczemVuckJDMFdqeDBHclZ3b1VfZU5LbXI4V1lfRFFzTHIxaWs4TUwwOTZ0MlNUX0F2b2dueWw3WHk0aTc1Yll6NDZ5TkVYRDBmbk1QT19SX1FJNEV3Y1RHMUJhS3JIMnU0bVpSWW5sN3kwazhvUnZqcGJQdUozVnF3OXRkSmdkVkxn?oc=5","date":"2021-01-04","type":"pipeline","source":"Massachusetts Biotechnology Council","summary":"Member Spotlight: Q&A with Forma Therapeutics - Massachusetts Biotechnology Council","headline":"Member Spotlight: Q&A with Forma Therapeutics","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}